Fig. 1From: Comparison of efficacy and safety of intravitreal ranibizumab and conbercept before vitrectomy in Chinese proliferative diabetic retinopathy patients: a prospective randomized controlled trialFlowchart showing the distribution of the study population. IVR, intravitreal ranibizumab; IVC, intravitreal conbercept; PPV, pars plana vitrectomyBack to article page